ClinicalTrials.gg
CompletedNCT02199379Updated Apr 14, 2015

A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy Subjects

A Phase 1 interventional study of Lenvatinib in Renal Impairment and Disease Severity, sponsored by Eisai Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-04-14.

Sponsored by Eisai Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 553 studies in Renal Insufficiency with a site in United States — 40 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.

Enrollment
282nd of 468
26 · median 32
Started
2011
with 29 others
Phase 1
232 of 553
14 open now
Registered
282nd of 553
by date

Among the 553 studies in Renal Insufficiency with a site in United States, this one is the 282nd largest by enrollment of the 468 interventional ones that give a count, is one of 30 that started in 2011, is one of 232 in phase 1, and was the 282nd registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

40 of the 553 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 553 studies in Renal Insufficiency with a site in United States, or all of them as a file.
02

Study summary

The purpose of this multicenter, open-label, non-randomized, single, oral dose, sequential-cohort study was to determine pharmacokinetics and safety of lenvatinib (24 mg) administered to healthy subjects and to subjects with renal impairment.

Read the detailed description

This is a multicenter, open-label, non-randomized, single-dose, sequential-cohort trial in subjects with renal impairment and healthy subjects. The study consists of two phases: A Pretreatment Phase and a Treatment Phase. The two periods in the Pretreatment Phase are: (1) the Screening Period (lasting up to 29 days), and (2) the Baseline Period (one day). The Treatment Period of the Treatment Phase lasts 8 days. The study will enroll a sufficient number of subjects so that 24 to 26 subjects complete the study. This will include six subjects with mild renal impairment (Group 1), six subjects with moderate renal impairment (Group 2), four to six subjects with severe renal impairment (Group 3) and eight subjects with normal renal function (Group 4). Subjects determined to be eligible for the protocol will receive a single 24-mg oral dose of E7080 on Day 1. Subjects will be discharged from clinical site on Day 8.

03

Conditions studied

  • Renal Impairment
  • Disease Severity

Browse trials for

Keywords

  • renal impairment
  • disease severity
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All subjects should meet all of the following criteria to be included in this study:

  1. Male or female subjects, ages 18 to 79, inclusive, at the time of
  2. , 18 to 40 kg/m2, inclusive, at Screening
  3. Nonsmokers and smokers who smoke no more than 10 cigarettes per day
  4. All females must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of beta-human chorionic gonadotropin [B-hCG] at the Screening Visit or within 72 hours before the first dose of study drug). Females of , if not practicing total abstinence or having a vasectomised partner with confirmed azoospermia, must agree to use two highly effective methods of : e.g., 1) an intrauterine device (IUD) or intrauterine system (IUS); 2) a barrier method such as a condom or occlusive cup (diaphragm or cervical/vault caps) plus spermicide (foam, gel, cream, etc.); 3) oral, injected, or implanted hormonal contraceptives throughout the entire study period and for 30 days after study drug discontinuation. Use of a double-barrier method (i.e., use at the same time of a condom plus occlusive cup [diaphragm or cervical/vault caps] plus spermicide [foam, gel, cream, etc.]) is accepted as two highly effective methods of contraception. The only subjects who will be exempt from this requirement are women (defined as women who have been amenorrheic for at least 12 consecutive months, in the appropriate age group, without other known or suspected primary cause) or subjects who have been sterilized surgically or who are otherwise proven sterile (i.e., bilateral tubal ligation with surgery at least 1 month prior to dosing, total hysterectomy, or bilateral oophorectomy with surgery at least 1 month prior to dosing). All women who are of and who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 4 weeks prior to dosing and must continue to use the same contraceptive during the study and for 30 days after study drug discontinuation.
  5. Male subjects who are partners of women of childbearing potential must use a condom plus spermicide and their female partners if of childbearing potential must use a highly effective method of contraception (see methods described in Inclusion Criterion No. 4) beginning at least one menstrual cycle prior to starting study drug, throughout the entire study period, and for 30 days after the last dose of study drug, unless the male subjects are totally sexually abstinent or have undergone a successful vasectomy with confirmed azoospermia or unless the female partners have been sterilized surgically or are otherwise proven sterile (see Inclusion Criterion No.4).
  6. Voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol.

For healthy subjects with normal renal function the following key inclusion criterion will also apply:

  1. greater than or equal to 90 mL/min.

For subjects with renal impairment, the following key inclusion criteria will also apply:

  1. Subjects must have a diagnosis of renal impairment that has been stable, without any change in disease status, for 60 days prior to study screening, as determined by the investigator.
  2. Mild (creatinine clearance, 60-89 mL/min), moderate (creatinine clearance, 30-59 mL/min), or severe (creatinine clearance, 15-29 mL/min) renal impairment
  3. Other than renal impairment, subjects must have no history of disease or condition (e.g., significant cardiac or hepatic dysfunction, diseases of the gastrointestinal tract or conditions which may impact drug absorption), as determined by the investigator.
  4. Subjects with a history of Type I or Type II diabetes are permissible, providing that, in the opinion of the investigator, they have stable disease. Subjects receiving insulin therapy are permissible provided that they have been on a stable treatment for at least 2 weeks prior to study enrollment and continuing through the study.
  5. corrected for heart rate (QTc) calculated by Fridericia's formula (QTcF) interval lesser than or equal to 500 msec at Screening and Baseline.
  6. Subjects may be enrolled with joint approval of the principal investigator (PI) and medical monitor based on subject history and stability of the renal impairment.

Exclusion criteria

Exclusion Criteria

Subjects who meet any of the following criteria will be excluded from this study:

All Subjects:

  1. Use of any new medication, including multivitamins, or drug within 14 days prior to the drug administration, or within five times the elimination half-life, whichever is longest, except combined oral and occasional use of paracetamol or ibuprofen within 14 days and any local anesthetic within 3 days before study drug administration. Current over-the-counter (OTC) drugs and prescription medication use is permitted, but must be stable and consistent for at least 14 days prior to Screening and throughout the study treatment period.
  2. Positive screening test
  3. Presence of acute, active liver disease or acute liver injury as indicated by (1) an abnormal liver function test, or (2) clinical or laboratory signs of acute, active hepatitis A, B, or C
  4. Systolic blood pressure greater than or equal to 160 mm Hg and/or diastolic blood pressure greater than or equal to 100 mm Hg for healthy subjects and subjects with mild renal impairment; systolic blood pressure greater than or equal to 180 mm Hg and/or diastolic blood pressure greater than or equal to 110 mm Hg for subjects with moderate and severe renal impairment. Readings are to be confirmed by repeat determinations one hour after the first measurement.

Healthy Subjects:

In addition to the Key Exclusion Criteria above for all subjects, other standard exclusion criteria for healthy subjects in Phase 1 studies will be used. These include:

  1. Subjects who had a illness which required medical treatment within 8 weeks or a clinically significant infection within 4 weeks of dosing
  2. Subjects with a history of myocardial infarction or active ischemic heart disease
  3. Subjects with a disease that may influence the outcome of the study, such as psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system, or subjects who have a congenital abnormality in metabolism within 4 weeks prior to dosing
  4. Gastrointestinal malabsorption or any other condition that may affect PK profiles of E7080 including a history of gastrointestinal surgery (hepatectomy, digestive organ resection, etc.) (Appendectomy and cholecystectomy are, however, permitted.)
  5. Subjects with a history of clinically significant drug or food allergies or presently experiencing significant seasonal allergies
  6. Subjects who experienced a weight loss or gain of greater than 10% between Screening and prior to dosing
  7. Subjects with a greater than 450 msec demonstrated on repeated (ECG) at Screening
  8. Subjects with level less than 12.0 g/dL
  9. Significant findings revealed by the history, physical or clinical laboratory testing
  10. Subjects with a known or suspected history of drug or alcohol misuse within 6 months prior to Screening, or who have a positive urine drug or alcohol test at Screening or Baseline
  11. Subjects who have consumed caffeinated beverages or food within 72 hours prior to dosing
  12. Receipt of another investigational drug or device within 4 weeks prior to dosing or five half-lives of the other investigational drug, whichever is longer
  13. Subjects who received blood products within 4 weeks, or donated blood within 8 weeks, or donated plasma within one week of dosing
  14. Subjects who have engaged in heavy exercise within 2 weeks prior to check-in (e.g., marathon runners, weight lifters, etc.)
  15. Subjects who are unwilling to abide by the requirements of the study, or in the opinion of the investigator, are not likely to complete the study.

Subjects with Renal Impairment:

  1. A history of renal transplant
  2. Known significant bleeding diathesis (e.g., history of recent bleeding from esophageal varices), which could preclude multiple venipuncture or deep intramuscular injection
  3. Significant acute, new onset illness within 2 weeks prior to study drug administration. In addition to the Key Exclusion Criteria above for All Subjects and for Subjects with Renal Impairment, other standard exclusion criteria for healthy subjects in Phase 1 studies will be used for subjects with renal impairment. These include:
  4. Subjects who had a clinically significant illness, where said illness is unrelated to their renal impairment, which required medical treatment within 8 weeks or a clinically significant infection within 4 weeks of dosing
  5. Subjects with a history of significant cardiovascular impairment: history of congestive heart failure greater than (NYHA) Class II; unstable angina; myocardial infarction or stroke within 6 months of the first dose of study drug; or cardiac arrhythmia requiring medical treatment
  6. Subjects with a disease that may influence the outcome of the study, such as psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system, or subjects who have a congenital abnormality in metabolism within 4 weeks prior to dosing
  7. Gastrointestinal malabsorption or any other condition that may affect PK profiles of E7080 including a history of gastrointestinal surgery (hepatectomy, digestive organ resection, etc.). (Appendectomy and cholecystectomy are, however, permitted.)
  8. Subjects with a known history of clinically significant drug or food allergies or presently experiencing significant seasonal allergies
  9. Subjects who experienced a weight loss or gain of greater than 10% between Screening and prior to dosing
  10. Significant findings revealed by the history, physical or clinical laboratory testing where said findings are unrelated to the subject's renal impairment
  11. Subjects with a known or suspected history of drug or alcohol misuse within 6 months prior to Screening, or who have a positive urine drug or alcohol test at Screening or Baseline
  12. Subjects who have consumed caffeinated beverages or food within 72 hours prior to dosing
  13. Receipt of another investigational drug or device within 4 weeks prior to dosing or five half-lives of the other investigational drug, whichever is longer
  14. Subjects who received blood products within 4 weeks, or donated blood within 8 weeks, or donated plasma within one week of dosing
  15. Subjects who have engaged in heavy exercise within 2 weeks prior to check-in (e.g., marathon runners, weight lifters, etc.)
  16. Subjects who are unwilling to abide by the requirements of the study, or in the opinion of the investigator, are not likely to complete the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Lenvatinib

    Lenvatinib will be taken as a single dose of 24 mg consisting of 2 x 10 mg and 1 x 4 mg capsules. Treatment will be administered orally with 240 mL of water following a 10-hour overnight fast.

    Drug: Lenvatinib

Interventions

  • Lenvatinib will be taken as a single dose of 24 mg consisting of 2 x 10 mg and 1 x 4 mg capsules. Treatment will be administered orally with 240 mL of water following a 10-hour overnight fast.

    Also known as: E7080

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics of lenvatinib: Cmax

    Time frame: Day 1 to Day 8

  2. Pharmacokinetics of lenvatinib: AUC(0-inf)

    Time frame: Day 1 to Day 8

  3. Pharmacokinetics of lenvatinib: AUC(0-t)

    Time frame: Day 1 to Day 8

Secondary outcomes

  1. Safety as Measured by Outcome of all Adverse Events (AEs)

    Time frame: Screening, Baseline and Treatment period (Day 1 to Day 8)

  2. Safety as Measured by Outcome of treatment-emergent AEs (TEAEs)

    Time frame: Screening, Baseline and Treatment period (Day 1 to Day 8)

  3. Safety as Measured by Outcome of serious adverse events (SAEs)

    Time frame: Screening, Baseline and Treatment period (Day 1 to Day 8)

  4. Safety as Measured by Laboratory Values

    Time frame: Screening, Baseline and Treatment period (Day 1 to Day 8)

  5. Safety as Measured by vital signs

    Time frame: Screening, Baseline and Treatment period (Day 1 to Day 8)

  6. Safety as Measured by ECGs

    Time frame: Screening, Baseline and Treatment period (Day 1 to Day 8)

  7. Safety as Measured by performance of physical examinations.

    Time frame: Screening, Baseline and Treatment period (Day 1 to Day 8)

07

Study locations

3 sites
  • Orlando, Florida 32809, United States
  • Minneapolis, Minnesota 55404, United States
  • Knoxville, Tennessee 37920, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2014
First posted
Jul 24, 2014
Start
Nov 2011
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Last update
Apr 14, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02199379
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Jul 24, 2014
Start date
Nov 2011
Primary completion
Oct 2012
Completion
Oct 2012
Last update
Apr 14, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion